This site is intended for health professionals only

Published on 12 January 2010

Share this story:
Twitter
LinkedIn

NicOx and TOPIGEN Pharmaceuticals terminate collaboration following the acquisition of TOPIGEN by Pharmaxis

teaser

NicOx today announced that NicOx and TOPIGEN Pharmaceuticals Inc have mutually terminated their collaboration for TPI 1020.

This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis announced yesterday.

Following two phase 2a studies that were conducted by TOPIGEN with TPI 1020 in patients with asthma and COPD,
NicOx and TOPIGEN had recently been in active discussions to explore potential new opportunities for the development
of TPI 1020 in a variety of respiratory indications. As a result of the strategic review of Pharmaxis and TOPIGEN’s development pipeline, they have decided not to move forward with the development of TPI 1020.

The licensing and co-development agreement between NicOx and TOPIGEN on TPI 1020, a novel anti-inflammatory
drug-candidate for respiratory indications, was signed in October 2005.

NicOx is a pharmaceutical company focused on the research, development and future commercialisation of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Chemical Entities (NCEs) for the potential treatment of inflammatory, cardiometabolic and ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NCE and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate for the relief of the signs and symptoms of osteoarthritis. NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug Administration (FDA) in September 2009 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) in December 2009, following the successful completion of three pivotal phase 3 studies. The NDA for naproxcinod was accepted for filing by the FDA in November 2009 and the FDA has set a target date of July 24 2010, for the completion of its review.

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-donating NCEs, which are in development internally and with partners, including Merck & Co., Inc., for the treatment of widespread eye diseases, cardiometabolic
diseases, hypertension and dermatological disease.

NicOx



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn